Barclays PLC trimmed its stake in shares of Gritstone Oncology Inc (NASDAQ:GRTS) by 56.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,354 shares of the company’s stock after selling 5,646 shares during the quarter. Barclays PLC’s holdings in Gritstone Oncology were worth $67,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in GRTS. Citigroup Inc. bought a new stake in shares of Gritstone Oncology in the 4th quarter valued at $28,000. Strs Ohio bought a new position in Gritstone Oncology during the fourth quarter worth $29,000. American International Group Inc. bought a new position in Gritstone Oncology during the fourth quarter worth $70,000. Riverhead Capital Management LLC bought a new position in Gritstone Oncology during the third quarter worth $141,000. Finally, Point72 Asset Management L.P. bought a new position in Gritstone Oncology during the third quarter worth $142,000. Institutional investors and hedge funds own 58.96% of the company’s stock.
Several brokerages recently issued reports on GRTS. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Gritstone Oncology in a report on Monday, April 1st. Berenberg Bank started coverage on shares of Gritstone Oncology in a report on Wednesday, March 27th. They set a “buy” rating on the stock. Finally, Raymond James started coverage on shares of Gritstone Oncology in a report on Thursday, March 14th. They set an “outperform” rating and a $20.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $22.20.
Gritstone Oncology (NASDAQ:GRTS) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.02. The company had revenue of $1.09 million for the quarter, compared to analysts’ expectations of $1.20 million. Analysts forecast that Gritstone Oncology Inc will post -2.71 EPS for the current year.
About Gritstone Oncology
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Read More: What is total return in investing?
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.